Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
DAWN Price/Volume Stats
| Current price | $6.25 | 52-week high | $16.76 |
| Prev. close | $6.16 | 52-week low | $6.08 |
| Day low | $6.08 | Volume | 2,740,200 |
| Day high | $6.32 | Avg. volume | 1,251,512 |
| 50-day MA | $7.54 | Dividend yield | N/A |
| 200-day MA | $11.85 | Market Cap | 633.51M |
DAWN Stock Price Chart Interactive Chart >
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Price Returns
| 1-mo | -8.63% |
| 3-mo | -49.02% |
| 6-mo | -51.96% |
| 1-year | -61.35% |
| 3-year | -17.55% |
| 5-year | N/A |
| YTD | -50.67% |
| 2024 | -13.22% |
| 2023 | -32.16% |
| 2022 | 27.72% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...